Xiaofen Pan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaofen Pan has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Bo Wang
1 shared publication- Bo Wang
Department of Medical Oncology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China
1 shared publication Chuyue Wang
Guangdong Institute of Gastroenterology, Guangzhou, China; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disease, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
1 shared publicationJiehao Liao
1 shared publicationMengyuan Zhu
Department of Oncology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
1 shared publication- Ping Yuan
Guangdong Institute of Gastroenterology, Guangzhou, China; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disease, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 19 (1) , 1732-1739
Long-Term Continuation Therapy with Nab-Paclitaxel and Bevacizumab ± Anti-PD-1 in Advanced Non-Small Cell Lung Cancer: Case Reports and Mechanistic Insights
Introduction: The role of nab-paclitaxel in non-small cell lung cancer (NSCLC) as long-term continuation therapy remains underexplored, particularly in combination with anti-angiogenic agents and immunotherapy. We present 2 cases of advanced NSCLC achieving prolonged progression-free survival with nab-paclitaxel-based regimens. Case presentation: Case 1 (ALK-positive) received nab-paclitaxel + bevacizumab every 4 weeks for more than 48 months. Case 2 (driver-negative) received nab-paclitaxel + bevacizumab + toripalimab every 6–8 weeks for 24 months. Both patients maintained partial regression of disease, minimal toxicity (no grade, ≥3 adverse events), and preserved quality of life. Conclusion: The literature review highlights synergistic mechanisms of chemotherapy, anti-angiogenesis, and immunotherapy, supported by trials such as IMpower150 and KEYNOTE-407. Low-dose, extended-interval nab-paclitaxel combined with anti-angiogenesis and immunotherapy may offer a feasible maintenance strategy, warranting validation in prospective trials.
- 1 January 2026
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 19 (1) , 1732-1739
Open AccessLong-Term Continuation Therapy with Nab-Paclitaxel and Bevacizumab ± Anti-PD-1 in Advanced Non-Small Cell Lung Cancer: Case Reports and Mechanistic Insights
Introduction: The role of nab-paclitaxel in non-small cell lung cancer (NSCLC) as long-term continuation therapy remains underexplored, particularly in combination with anti-angiogenic agents and immunotherapy. We present 2 cases of advanced NSCLC achieving prolonged progression-free survival with nab-paclitaxel-based regimens. Case presentation: Case 1 (ALK-positive) received nab-paclitaxel + bevacizumab every 4 weeks for more than 48 months. Case 2 (driver-negative) received nab-paclitaxel + bevacizumab + toripalimab every 6–8 weeks for 24 months. Both patients maintained partial regression of disease, minimal toxicity (no grade, ≥3 adverse events), and preserved quality of life. Conclusion: The literature review highlights synergistic mechanisms of chemotherapy, anti-angiogenesis, and immunotherapy, supported by trials such as IMpower150 and KEYNOTE-407. Low-dose, extended-interval nab-paclitaxel combined with anti-angiogenesis and immunotherapy may offer a feasible maintenance strategy, warranting validation in prospective trials.
- 5 December 2025
- Published by Elsevier in Experimental Cell Research
- Vol. 455 (2) , 114850
Bioinformatics analysis of PLAUR and its oncogenic role of promoting colorectal cancer progression through the AKT/p53 signaling
- 5 December 2025
- Published by Elsevier in Experimental Cell Research
- Vol. 455 (2) , 114850
Bioinformatics analysis of PLAUR and its oncogenic role of promoting colorectal cancer progression through the AKT/p53 signaling
- Open Access
- 25 October 2025
- Published by The Korean Society of Gastroenterology in The Korean Journal of Gastroenterology
- Vol. 85 (4) , 497-505
The Efficacy and Safety of Endostatin Combined with Definitive Chemoradiotherapy for Unresectable Esophageal Squamous Cell Carcinoma: A Retrospective Analysis
Mengyuan Zhu, Qun Li and Xiaofen Pan. Korean J Gastroenterol 2025;85:497-505. https://doi.org/10.4166/kjg.2024.150
- 25 October 2025
- Published by The Korean Society of Gastroenterology in The Korean Journal of Gastroenterology
- Vol. 85 (4) , 497-505
Open AccessThe Efficacy and Safety of Endostatin Combined with Definitive Chemoradiotherapy for Unresectable Esophageal Squamous Cell Carcinoma: A Retrospective Analysis
Mengyuan Zhu, Qun Li and Xiaofen Pan. Korean J Gastroenterol 2025;85:497-505. https://doi.org/10.4166/kjg.2024.150